Pancreatic Cancer Research

ResearcherJiangsu Province HospitalActive in the last 2 years

Yi Miao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2542-8663; OpenAlex author ID A5100671685, A5125476605. Sources: ClinicalTrials.gov.

Their work

Papers
88 (first author 2, last author 34)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
181
Papers, trials and grants by year

2011: 6 papers · 2012: 2 papers · 2013: 2 papers · 2014: 5 papers · 2015: 3 papers · 2016: 5 papers, 1 trial · 2017: 9 papers · 2018: 13 papers · 2019: 5 papers · 2020: 9 papers · 2021: 12 papers · 2022: 6 papers · 2023: 2 papers · 2024: 3 papers · 2025: 4 papers · 2026: 2 papers

Papers 50 of 88

  1. An Insulin-Exosome-TNFAIP8 Axis Drives Stromal Fibrosis and Therapeutic Resistance in Pancreatic Cancer. Last author DOI 10.1002/advs.202515606↗
  2. Pyogenic liver abscess following Roux-en-Y choledochojejunostomy in advanced pancreatic cancer: a retrospective case series First author DOI 10.21203/rs.3.rs-8726704/v1↗
  3. LIM domain only 7: a novel driver of immune evasion through regulatory T cell differentiation and chemotaxis in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41418-024-01358-7↗
  4. USP19 potentiates autophagic cell death via inhibiting mTOR pathway through deubiquitinating NEK9 in pancreatic cancer. Co-author DOI 10.1038/s41418-024-01426-y↗
  5. Correction: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. Last author DOI 10.1186/s12967-025-06581-5↗
  6. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  7. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  8. Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Results From an International Multicenter Study. Co-author DOI 10.1200/jco.23.02313↗
  9. [Short-term outcomes of the TRIANGLE operation after neoadjuvant chemotherapy in locally advanced pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230615-000234↗
  10. Cancer-testis gene STK31 is regulated by methylation and promotes the development of pancreatic cancer. Co-author DOI 10.1002/cam4.5472↗
  11. Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. Co-author DOI 10.1016/j.sopen.2023.03.001↗
  12. Incidence of Pancreatic Cancer by Age and Sex in the US From 2000 to 2018. Last author DOI 10.1001/jama.2022.2312↗
  13. Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China. Last author DOI 10.1001/jamanetworkopen.2021.48721↗
  14. A histopathological study of artery wall involvement in pancreatic cancer surgery. Last author DOI 10.1007/s00423-022-02689-0↗
  15. The distinct genetic features of pancreatic cancer in Chinese population. Last author DOI 10.1016/j.ebiom.2022.103960↗
  16. Biological functions, mechanisms, and clinical significance of circular RNA in pancreatic cancer: a promising rising star. Co-author DOI 10.1186/s13578-022-00833-3↗
  17. Suppressive effect of YY1-mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2022.13577↗
  18. Sub-adventitial divestment technique for resecting artery-involved pancreatic cancer: a retrospective cohort study. Last author DOI 10.1007/s00423-021-02080-5↗
  19. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST… Co-author DOI 10.1016/j.pan.2021.05.300↗
  20. Periarterial divestment in pancreatic cancer surgery. Co-author DOI 10.1016/j.surg.2020.08.030↗
  21. Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer. Co-author DOI 10.1038/s41388-021-01741-5↗
  22. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Co-author DOI 10.1038/s41388-021-02040-9↗
  23. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer. Co-author DOI 10.1155/2021/6530298↗
  24. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. Co-author DOI 10.1158/1078-0432.ccr-20-1746↗
  25. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Co-author DOI 10.1186/s12943-021-01333-7↗
  26. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02063-w↗
  27. Opposite Roles of Tumor Cell Proliferation and Immune Cell Infiltration in Postoperative Liver Metastasis of PDAC. Last author DOI 10.3389/fcell.2021.714718↗
  28. CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.832315↗
  29. Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis. Co-author DOI 10.3390/cancers14010057↗
  30. Higher miR-543 levels correlate with lower STK31 expression and longer pancreatic cancer survival. Co-author DOI 10.1002/cam4.3559↗
  31. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Co-author DOI 10.1002/ijc.32827↗
  32. Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis. Last author DOI 10.1007/s00268-019-05325-z↗
  33. Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine. Last author DOI 10.1016/j.biopha.2019.109521↗
  34. EFNB2 facilitates cell proliferation, migration, and invasion in pancreatic ductal adenocarcinoma via the p53/p21 pathway and EMT. Last author DOI 10.1016/j.biopha.2020.109972↗
  35. Linc01232 promotes the metastasis of pancreatic cancer by suppressing the ubiquitin-mediated degradation of HNRNPA2B1 and activating the A-Raf-induced MAPK/ERK… Co-author DOI 10.1016/j.canlet.2020.08.001↗
  36. The YY1/miR-548t-5p/CXCL11 signaling axis regulates cell proliferation and metastasis in human pancreatic cancer. Co-author DOI 10.1038/s41419-020-2475-3↗
  37. Optimization of internal reference genes for qPCR in human pancreatic cancer research. Co-author DOI 10.21037/tcr.2020.02.48↗
  38. [Comparison of radical antegrade modular pancreatosplenectomy with conventional distal pancreatectomy for pancreatic adenocarcinoma of the body and tail]. Last author DOI 10.3760/cma.j.cn112139-20200413-00301↗
  39. Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Last author DOI 10.1002/cam4.2145↗
  40. Central pancreatectomy for early-stage pancreatic ductal adenocarcinoma: a single-center case-control study. Last author DOI 10.1007/s00423-019-01766-1↗
  41. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Co-author DOI 10.1016/j.canlet.2018.11.007↗
  42. YY1 inhibits the migration and invasion of pancreatic ductal adenocarcinoma by downregulating the FER/STAT3/MMP2 signaling pathway. Co-author DOI 10.1016/j.canlet.2019.07.019↗
  43. YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways. Co-author DOI 10.1038/s41416-019-0604-5↗
  44. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Last author DOI 10.1002/ijc.31173↗
  45. Long non-coding RNA lnc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. Last author DOI 10.1002/ijc.31657↗
  46. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Co-author DOI 10.1007/s11523-018-0578-x↗
  47. Plasma miRNAs in diagnosis and prognosis of pancreatic cancer: A miRNA expression analysis. Last author DOI 10.1016/j.gene.2018.06.037↗
  48. Thymidine kinase 1 silencing retards proliferative activity of pancreatic cancer cell via E2F1-TK1-P21 axis. Last author DOI 10.1111/cpr.12428↗
  49. PIK3R3 Promotes Metastasis of Pancreatic Cancer via ZEB1 Induced Epithelial-Mesenchymal Transition. Last author DOI 10.1159/000489382↗
  50. ALKBH5 Inhibits Pancreatic Cancer Motility by Decreasing Long Non-Coding RNA KCNK15-AS1 Methylation. Last author DOI 10.1159/000491915↗

Trials 1

  1. T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System Principal investigator NCT02662348↗

Closest collaborators

The 25 strongest of 181 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kuirong Jiang · 49 shared papers, 2011–2025 · strength 4.79
  2. Zipeng Lu · 33 shared papers, 2011–2025 · strength 3.57
  3. Jishu Wei · 27 shared papers, 2011–2025 · strength 2.68
  4. Lingdi Yin · 18 shared papers, 2016–2026 · strength 2.52
  5. Yunpeng Peng · 18 shared papers, 2014–2025 · strength 1.72
  6. Baobao Cai · 12 shared papers, 2013–2023 · strength 1.65
  7. Jingjing Zhang · 19 shared papers, 2011–2025 · strength 1.60
  8. Wentao Gao · 19 shared papers, 2011–2025 · strength 1.58
  9. Junli Wu · 16 shared papers, 2011–2025 · strength 1.55
  10. Min Tu · 15 shared papers, 2013–2025 · strength 1.50
  11. Wanli Ge · 12 shared papers, 2018–2022 · strength 1.34
  12. Xumin Huang · 12 shared papers, 2019–2021 · strength 1.31
  13. Hao Yuan · 13 shared papers, 2017–2022 · strength 1.17
  14. Guodong Shi · 13 shared papers, 2017–2021 · strength 1.11
  15. Pengfei Wu · 11 shared papers, 2017–2024 · strength 1.10
  16. Guangfu Wang · 7 shared papers, 2019–2025 · strength 1.10
  17. Qun Chen · 10 shared papers, 2019–2022 · strength 1.08
  18. Chunhua Xi · 9 shared papers, 2016–2026 · strength 1.04
  19. Lingdong Meng · 9 shared papers, 2019–2022 · strength 1.01
  20. Peng Shen · 9 shared papers, 2019–2022 · strength 0.97
  21. Kai Zhang · 6 shared papers, 2019–2024 · strength 0.89
  22. Shangnan Dai · 5 shared papers, 2020–2025 · strength 0.78
  23. Hao Gao Gao · 5 shared papers, 2019–2023 · strength 0.66
  24. Kai Zhang · 4 shared papers, 2020–2025 · strength 0.64
  25. Dongxue Geng · 1 shared paper, 2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.